K-Ras(G12C) inhibitor 6 is an inhibitor of the oncogene KRAS.
Its family of inhibitors allosterically control the GTP affinity of mutant K-Ras which is a driver in many cancers.
In recent years, significant research efforts have focused on finding effective inhibitors for the Kras-G12C mutation leading to the FDA-approval of G12C-KRAS targeting therapies including sotorasib (Lumakras) and Adagrasib (MRTX849)
K-Ras(G12C) inhibitor 6 is an irreversible inhibitor subverting the native nucleotide preference to favour GDP over GTP.